

Personal Information



Walter Tsang-Wu Liu

Address: National Health Research Institutions

Country: Taiwan

Curriculum Vitae

Current Position:

- Attending Physician and Deputy Director, National Institute of Cancer Research, National Health Research Institutions
- Director, Operation Center of Taiwan Cooperative Oncology Group

Education:

- Medical College National Taiwan University, M.D

Professional Experiences:

- Director, Taiwan Cooperative Oncology Group, NHRI
- Associate Investigator and Attending Physician, National Institute of Cancer Research, National Health Research Institutes
- Head, Department of Research Planning and Development, National Health Research Institutes
- Member, Advisory Committee, Division of Medicinal Products Food and Drug Administration; chairman of the subcommittee for Review and Approval of Orphan Drugs, Health Promotion Administration, Ministry of Health and Welfare
- President, Chinese Oncology Society
- Deputy Director, National Institute of Cancer Research, National Health Research Institutes

Specialty:

- Hematology/medical oncology, clinical trial

Research Interests:

Dr. Liu's main research interest is the anticancer experimental therapy, especially on the cancers prevalent in Taiwan. In recent years, Dr. Liu has been interested in cancer care quality and is the principal investigator to establish Accreditation System of Cancer Care Programs in Taiwan.

Refereed Paper (2016-2017):

1. Chao YK, Ku HY, Chen CY, Liu TW. Induction therapy before surgery improves survival in patients with clinical T3N0 esophageal cancer: a nationwide study in Taiwan. *Diseases of the Esophagus*. 2017 Dec 1; 30(12):1-7.

2. Hung YN, Wen FH, Liu TW, Chen JS, Tang ST. Hospice Exposure Is Associated with Lower Healthcare Expenditures in Taiwanese Cancer Decedents' Last Year of Life: A Population-Based Retrospective Cohort Study. *J Pain Symptom Manage*. 2017 Oct 25.

3. Lin SM, Ku HY, Chang TC, Liu TW, Hong JH. The prognostic impact of overall treatment time on disease outcome in uterine cervical cancer patients treated primarily with concomitant chemoradiotherapy: a nationwide Taiwanese cohort study. *Oncotarget*. 2017 Jul 27; 8(49): 85203-85213.

4. von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators (Liu TW). Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. *N Engl J Med*. 2017 Jul 13; 377(2):122-131.

5. Liu TW, Wen FH, Wang CH, Hong RL, Chow JM, Chen JS, Chiu CF, Tang ST. Terminally Ill Taiwanese cancer patients' and family caregivers' agreement on patterns of life-sustaining treatment preferences is poor to fair and declines over a decade: Results from two independent cross-sectional studies. *Journal of Pain and Symptom Management*. 2017 Jul; 54(1):35-45.e4.

6. Chien LH, Tseng TJ, Chen CH, Jiang HF, Tsai FY, Liu TW, Hsiung CA, Chang IS. Comparison of annual percentage change in breast cancer incidence rate between Taiwan and the United States-A smoothed Lexis diagram approach. *Cancer Medicine*. 2017 Jul; 6(7):1762-1775.

7. Kuan FC, Lai CH, Ku HY, Wu CF, Hsieh MC, Liu TW, Yeh CY, Lee KD. The survival impact of delayed surgery and adjuvant chemotherapy on stage II/III rectal cancer with pathological complete response after neoadjuvant chemoradiation. *International Journal of Cancer*. 2017 Apr; 140(7):1662-1669.

8. Liao CT, Wen YW, Yang LY, Lee SR, Ng SH, Liu TW, Tsai ST, Tsai MH, Lin JC, Chen PR, Lou PJ, Wang CP, Chu PY, Hwang TZ, Leu YS, Tsai KY, Terng SD, Chen TM, Wang CH, Chien CY, Chen WC, Lee LY, Lin CY, Wang HM, Hsieh CH, Tsao CK, Fang TJ, Huang SF, Kang CJ, Chang KP, Yen TC. Comparative clinical outcomes of Taiwanese patients with resected buccal and tongue squamous cell carcinomas. *Oral Oncology*. 2017 Apr; 67:95-102.

9. Hung YN, Liu TW, Wen FH, Chou WC, Tang ST. Escalating health care expenditures in cancer decedents' last year of life: A decade of evidence from a retrospective population-based cohort study in Taiwan. *Oncologist*. 2017 Apr; 22(4):460-469.

10. Liao CT, Wen YW, Lee SR, Liu TW, Tsai ST, Tsai MH, Lin JC, Lou PJ, Chu PY, Leu YS, Tsai KY, Terng SD, Chen TM, Wang CH, Chien CY, Chen WC, Lee LY, Lin CY, Wang HM, Ng SH, Lin CH, Fang TJ, Huang SF, Kang CJ, Chang KP, Yang LY, Yen TC. Taiwan Oral Cancer Advisory

Group. Clinical Outcomes of Taiwanese Patients with cT4 Oral Cavity Squamous Cell Carcinoma: Toward the Identification of the Optimal Initial Treatment Approach for cT4b Patients. *Annals of Surgical Oncology*. 2017 Mar; 24(3):785-793.

11.Liao CT, Chen HN, Wen YW, Lee SR, Ng SH, Liu TW, Tsai ST, Tsai MH, Lin JC, Lou PJ, Wang CP, Chu PY, Leu YS, Tsai KY, Terng SD, Chen TM, Wang CH, Chien CY, Chen WC, Lee LY, Lin CY, Wang HM, Lin CH, Fang TJ, Huang SF, Kang CJ, Chang KP, Yang LY, Yen TC. Association between the diagnosis-to-treatment interval and overall survival in Taiwanese patients with oral cavity squamous cell carcinoma. *European Journal of Cancer*. 2017 Feb; 72:226-234.

12.Wang HY, Chang YL, Cheng CC, Chao MW, Lin SI, Pan SL, Hsu CC, Liu TW, Cheng HC, Tseng CP, Liu SJ, Tsai HJ, Chang HY, Hsu JT. Glucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer. *Oncotarget*. 2016 Dec; 7(52):85917-85928.

13.Hung YN, Cheng SH, Liu TW, Chang WC, Chen JS, Tang ST. Trend in and correlates of undergoing radiotherapy in Taiwanese cancer patients' last month of life. *J Pain Symptom Manag*. 2016 Sep; 52(3):395-403.

14.Liu TW, Hung YN, Earle CC, Liu TP, Liu LN, Tang ST. Characteristics and correlates of increasing use of surgery in Taiwanese cancer patients' last month of life, 2001-2010. *Ann Surg*. 2016 Aug; 264(2):283-90.

15.Hsu CH, Tseng CH, Chiang CJ, Hsu KH, Tseng JS, Chen KC, Wang CL, Chen CY, Yen S, Chiu CH, Huang MS, Yu CJ, Tsai YH, Chen JS, Tsai CM, Chou TY, Lin KC, Tsai MH, Lee WC, Ku HY, Liu TW, Yang TY, Chang GC. Characteristics of young lung cancer: Analysis of Taiwan's nationwide lung cancer registry focusing on epidermal growth factor receptor mutation and smoking status. *Oncotarget*. 2016 Aug; 7(29):46628-46635.

16.Hung YN, Liu TW, Lin DT, Chen YC, Chen JS, Tang ST. Receipt of life-sustaining treatments for Taiwanese pediatric patients who died of cancer in 2001 to 2010: A Retrospective Cohort Study. *Medicine (Baltimore)*. 2016 Apr; 95(16):e3461.

17.Liu TW, Chen LT. S-1 with leucovorin for gastric cancer: How far can it go? *Lancet Oncology*. 2016 Jan; 17(1):12-14.

18.Chen MH, Lin J, Hsiao CF, Shan YS, Chen YC, Chen LT, Liu TW, Li CP, Chao Y. A phase II study of sequential capecitabine plus oxaliplatin followed by docetaxel plus capecitabine in patients with unresectable gastric adenocarcinoma: The TCOG 3211 Clinical Trial. *Medicine (Baltimore)*. 2016 Jan;95(3):e2565.